← Leaderboards
Lynn Kirkpatrick
Ensysce Biosciences, Inc.
$26,849,903
Attributed
$26,849,903
Total exposure
7
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $8.5M · FY2012–25$10M$7.5M$5M$2.5M$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$26,849,903 · 7
By mechanism
UG3$10,592,211 · 2
U01$9,861,616 · 1
UH3$5,585,570 · 1
R43$810,506 · 3
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Design”
- Lawrence Corey · Fred Hutchinson Cancer Center$736,542,541
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$460,267,569
- Jeffrey P Krischer · University Of South Florida$427,700,530
- David R. Weir · University Of Michigan At Ann Arbor$385,316,144
Research focus
DesignPharmaceutical PreparationsDrug KineticsDoseNew TechnologyClinical TrialsPre-ClinicalFormulationBiological SciencesOpiate AddictionPhysiologicalIn VivoOverdosePillCessation Of LifeOpioidMolecularBaseEnzymesExposure ToOralOral AdministrationPlasmaPrescription Opioid Abuse
Grant awards (11)
PF614-MPAR: clinical development of opioid with oral overdose protection$5,288,921
U01 · FY2025 · DA · contact PI
PF614-MPAR: clinical development of opioid with oral overdose protection$4,572,695
U01 · FY2024 · DA · contact PI
PF614 MPAR Abuse Deterrent opioid prodrug with overdose protection: Pre-Clinical Development and Phase 1 Clinical Trial$2,794,315
UH3 · FY2022 · DA · contact PI
PF614 MPAR Abuse Deterrent opioid prodrug with overdose protection: Pre-Clinical Development and Phase 1 Clinical Trial$2,791,255
UH3 · FY2021 · DA · contact PI
R-methadone-TAAP/MPAR: an abuse deterrent methadone prodrug with overdose protection: Pre-Clinical Development and Phase 1 Clinical Trial$5,389,398
UG3 · FY2019 · DA · contact PI
PF614 MPAR Abuse Deterrent opioid prodrug with overdose protection: Pre-Clinical Development and Phase 1 Clinical Trial$2,949,024
UG3 · FY2019 · DA · contact PI
PF614 MPAR Abuse Deterrent opioid prodrug with overdose protection: Pre-Clinical Development and Phase 1 Clinical Trial$129,800
UG3 · FY2019 · DA · contact PI
PF614 MPAR Abuse Deterrent opioid prodrug with overdose protection: Pre-Clinical Development and Phase 1 Clinical Trial$2,123,989
UG3 · FY2018 · DA · contact PI
Inhibiting PLEKHA7 for mutant KRAS therapy$225,000
R43 · FY2014 · CA · contact PI
Targeting mutant KRAS for cancer therapy$287,434
R43 · FY2013 · CA · contact PI
Optimization of SWCNT/siRNA complex formulation for tumor accumulation$298,072
R43 · FY2012 · CA · contact PI